[en] BACKGROUND: 6-Mercaptopurine (6-MP) and its prodrug azathioprine (AZA) have proven efficacy in the treatment of Crohn disease (CD). The immunosuppressive properties of AZA/6-MP are mediated by the intracellular metabolism of 6-MP into its active metabolites, 6-thioguanine nucleotides (6TGN) and 6methylmercaptopurine (6-MMP). Preliminary studies have suggested that the red blood cell concentration of 6TGN (RBC 6TGN) is a potential guide to therapy. The aims of the study were to evaluate the RBC 6TGN concentrations in adult patients with CD under long-term AZA/6-MP therapy and to correlate it with response to treatment and haematological parameters. METHODS: Twenty-eight CD patients treated for at least 3 months with AZA/6-MP were prospectively studied. Patients were separated into three main groups: group 1 (n = 19), corresponding to quiescent CD receiving AZA (dose: 2.05 +/- 0.4 mg/kg/day for a mean of 28.6 +/- 25 months) or 6-MP (dose: 1.4 +/- 01 mg/kg/day for a mean of 7.5 +/- 3.5 months) alone; group 2 (n = 6), corresponding to quiescent CD treated by AZA (dose: 2.14 +/- 0.5 mg/kg/day for a mean of 29.5 +/- 22 months) with oral steroids; and group 3 (n = 3), corresponding to active CD on AZA (dose: 1.94 +/- 0.6 mg/kg/day for a mean of 31.3 +/- 35 months) as the only treatment. An assessment was also made by merging groups 1 and 2 forming a larger group of patients (n = 25) defined by clinical remission and groups 2 and 3 forming a larger group of patients (n = 9), non-complete responders with AZA/6-MP alone. Crohn disease index activity (CDAI), blood samples for full blood count and differential white cell count and measurement of RBC 6TGN and 6-MMP concentrations were evaluated at inclusion and at 6 months (n = 17). RBC 6TGN were measured using high performance liquid chromatography (HPLC) on heparinized blood. RESULTS: The baseline characteristics of the three groups of patients were similar. There was no significant difference among the three groups of patients regarding the dose and the duration of immunosuppressive treatment. There was no significant difference between groups according to various parameters tested. Particularly, the median RBC 6TGN concentration at inclusion was similar in the three groups of patients (166 (105-688), 183 (90-261) and 160 (52-194) pmol/8 x 10(8) RBC, respectively). The majority of patients had no detectable level of 6-MMP metabolite, except for 3 patients. There was also no difference between merging groups. Furthermore, there was no significant correlation between RBC 6TGN concentrations and the various biological parameters tested except for the mean erythrocyte volume. At 6 months, all patients of group 1 remained in remission and median RBC 6TGN concentration remained stable. No side effects were observed. CONCLUSIONS: There is, contrary to preliminary studies, a broad overlap in RBC 6TGN levels as well as for haematological parameters in patients in remission or not and responders or not to AZA/6-MP therapy. This suggests, beside a variability in the metabolism of these drugs, the existence of complex mechanisms of action. Nevertheless, beside the use of RBC 6TGN determination to confirm compliance to therapy, this dosage could be useful in non-responding patients, allowing, in absence of leukopenia, to increase the dose of AZA/6-MP safely.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Belaiche, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Desager, J. P.
Horsmans, Y.
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Language :
English
Title :
Therapeutic Drug Monitoring of Azathioprine and 6-Mercaptopurine Metabolites in Crohn Disease
Pearson D.C., May G.R., Fick G.H., Sutherland L.R. (1995) Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 123:132-142.
Ewe K., Press A.G., Singe C.C., Stufler M., Ueberschaer B. (1993) Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 105:367-372.
Korelitz B.I., Adler D.J., Mendelsohn R.A., Sacknoff A.L. (1993) Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol 88:1198-1205.
Blondel-Kucharki F., Chircop C., Marquis P., Colombel J.F., Gendre J.P. (1999) Qualité de vie au cours de la maladie de Crohn. Etude prospective longitudinale de 231 patients. Gastroenterol Clin Biol 23.
Sandborn W.J. (1998) Azathioprine: State of art in inflammatory bowel disease. Scand J Gastroenterol 33(SUPPL. 225):92-99.
Cuffari C., Théort Y., Latour S., Seidman G. (1996) 6-Mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity. Gut 39:401-406.
Gower-Rousseau C., Salomez J.L., Dupas J.L., Marti R., Nuttens M.C., Votte A. (1994) Incidence of inflammatory bowel disease in northern France (1988-1990). Gut 35:1433-1438.
Franchimont D., Louis E., Croes F., Belaiche J. (1998) Clinical pattern of corticosteroid dependent Crohn's disease. Eur J Gastroenterol Hepatol 10:821-825.
Lennard L., Singleton H.J. (1992) High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: Quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr B Biomed Appl 583:83-90.
Dubinsky M.C., Lamothe S., Yang H.Y., Targan S.R., Sinnett D., Théort Y. (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118:705-713.
Cuffari C., Picco M., Hunt S., Bayless T. (1999) Azathioprine metabolite levels predict clinical responsiveness to therapy in IBD. Gastroenterology 116.
Barbe L., Marteau Ph., Lémann M., Bouhnik Y., Allez M., Coffin B. (1998) Dose raising of azathioprine beyond 2.5 mg/kg/day in Crohn's disease patients who fail to improve with a standard dose. Gastroenterology 114.
Colonna T., Korelitz B.I. (1994) The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 89:362-366.
Sandborn W.J., Tremaine W.J., Wolf D.C., Targan S.R., Sninski C.A., Sutherland R.S. (1999) Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology 117:527-535.
Cattan S., Lémann M., Thuillier F., Bengoufa D., Rabian C., Ngo Y. (1998) Dosage de la 6-mercaptopurine et étude des sous-populations lymphocytaires sanguines au cours du traitement par l'azathioprine dans la maladie de Crohn. Gastroenterol Clin Biol 22:160-167.
Lillemans J.S., Lennard L. (1994) Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. Lancet 343:1188-1190.
Lennard L., Lilleyman J.S. (1989) Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 7:1816-1823.
Bergan S., Rugstad H.E., Bentdal O., Sodal G., Hartmann A., Leivestad T. (1998) Monitored high-dose azathioprine treatment reduce acute rejection episodes after renal transplantation. Transplantation 66:334-339.
Schutz E., Gummert J., Amstrong V.W., Mohr F.W., Oellerich M. (1996) Azathioprine pharmacogenetics: The relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur J Clin Chem Clin Biochem 34:199-205.
Sandborn W.J. (1997) 6-MP metabolite levels: A potential guide to Crohn's disease therapy. Gastroenterology 113:690-692.
Decaux G., Propert F., Horsmans Y., Desager J.P. (2000) Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med 135:256-262.